Drugnet Europe 73. by unknown
In this issue…
January–March
2011 
Mephedrone ban across the EU
Europe has responded to rising concern over the use 
of the synthetic drug mephedrone by subjecting it to 
‘control measures and criminal penalties’ throughout 
the EU. In a Decision of 2 December, the Council of 
the EU banned the drug, calling on Member States 
to introduce controls in line with their national law (1).
The announcement followed a proposal from the 
European Commission on 20 October that 
governments should act to stop the free spread of 
mephedrone. Reacting to the ban, European 
Commission Vice-President Viviane Reding said:  
‘The EU has shown today that we can act quickly to 
stop this kind of drug from taking more lives’.
The Decision is based on the findings of a formal 
risk-assessment report on mephedrone prepared in 
July 2010 by the EMCDDA Scientific Committee, 
with the participation of experts from the Member 
States, the European Commission, Europol and the 
European Medicines Agency (see page 7).  
The report examined the health and social risks of 
the drug as well as information on international 
trafficking and the involvement of organised crime.  
It concluded that, while there is limited scientific 
evidence on its overall health and social risks, and 
that further studies are needed, mephedrone can 
cause acute health problems and potentially lead to 
dependency.
Following the Decision, EU Member States have 
one year to take the necessary measures to submit 
mephedrone to controls. At the time of the Council 
Decision, 16 Member States had already 
controlled it.
New developments in wastewater analysis — an 
emerging science with the potential to monitor levels 
of illicit drug use in the community — were explored 
at the latest European meeting on the topic hosted by 
the EMCDDA on 28 January.
Thanks to technological advances and more sensitive 
detection techniques developed over the last 30 
years, experts today can detect and quantify drug 
residues in liquids, even at very low concentrations (1).
By sampling a known source of wastewater —  
for example a sewage influent to a wastewater 
treatment plant — scientists can obtain precise 
estimates of the total quantity of drugs consumed by a 
community by measuring the levels of illicit drug 
metabolites excreted in urine. The method also has the 
potential to monitor trends and changing consumption 
habits in real time, while preserving the anonymity of 
the individuals involved.
While such methods do not provide the type of 
detailed consumption data currently yielded by drug 
surveys (e.g. lifetime, recent, current use), their ability 
to pinpoint total consumption rates in a given 
population make them a useful complement to existing 
methods for studying drug use trends in Europe.
Opening the meeting in Lisbon, EMCDDA Director 
Wolfgang Götz said: ‘Drug use presents us with a 
moving target and is difficult to observe. It is by nature 
a covert and often stigmatised activity, and no single 
measure can provide us with the full picture. The 
possibility that a new technique for estimating illicit 
drug use might be added to our existing multi-indicator 
repertoire is, therefore, an exciting and promising 
prospect’.
Over 20 analytical chemists, epidemiologists and 
engineers from Europe and the USA participated in 
the event. They reviewed the methodological and 
technological progress achieved since the first 
European meeting on this topic, held at the EMCDDA 
in 2007.
The participants reported on an exploratory 
collaboration project aimed at generating comparable 
data from several European cities, for cocaine, heroin, 
amphetamine, methamphetamine and MDMA.
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Wastewater analysis: ‘an exciting and promising prospect’.
Continued on page 8
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(1) For more, see http://www.emcdda.europa.eu/drug-situation/
new-drugs
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Drug situation
Monitoring illicit drug supply in Europe
Measuring cannabis dependence in the general population
SMART: developing standard measures of alcohol use 
The need to scale up the monitoring of illicit 
drug supply in Europe is an important 
component of the current EU action plan and 
EMCDDA work programme 2010–12. In 
October 2010, the first European conference 
on drug supply indicators (1) initiated work on 
the conceptualisation of technically sound 
and sustainable indicators in this area of key 
importance for European drug policy.
According to the strategy adopted, the overall 
conceptual framework to monitor illicit drug 
supply will integrate three components: drug 
markets, drug-related crime and drug supply 
reduction. Special attention will be given to 
the possible standardisation, extension and 
improvement of existing data-collection 
systems and targeted research will be used to 
improve understanding of the topic. Three 
working groups, supported by the EMCDDA, 
will produce a roadmap in 2011 comprising 
short, medium and long-term monitoring 
objectives for the three areas. 
In the area of drug markets, future activities will 
focus, among others, on improving drug price 
and purity data sets and exploring the potential 
of forensic science. The development of a 
European standard monitoring instrument on 
drug law offences and of indicators on intra-
European drug production will be key in the 
drug-related crime area, together with defining 
priorities for research. Policing and criminal 
justice agencies will play a central role in drug 
supply reduction. Work in this under-researched 
area will begin with a mapping exercise to 
provide an overview of drug supply reduction 
activities in Europe. As a first step, the 
EMCDDA will launch in 2011 a survey on the 
existence and role of specialised law-
enforcement drug units.
Chloé Carpentier
(1) Organised by the European Commission and the 
EMCDDA, with the active involvement of Europol.
See results at: www.emcdda.europa.eu/publications/
supply-indicator-conference-2010/conclusions
The EMCDDA estimates that there are at least  
4 million Europeans (1 % of all adults) using 
cannabis on a daily or almost daily basis.  
Most of these are males, reaching up to 5–7 % 
of young men (15–34 years) in some countries. 
Studies show that between a third and one half 
of daily cannabis users fulfil dependence criteria.
In order to formulate adequate policies and 
responses in this field, a reliable and valid 
measure of cannabis dependence or abuse in 
the population is essential. The EMCDDA is 
currently collaborating with national experts (1)  
to develop a common European measurement 
methodology, with results expected at the end 
of the year.
Use of alcohol is often closely associated to 
drug use, particularly among young people 
and in recreational settings (1). Today, 
population surveys on alcohol use and 
related problems are carried out regularly in 
almost all countries of the EU and European 
Economic Area (EEA). However, comparison 
of results is hindered by the current lack of 
standardised methodology. To address this 
issue, the ‘Standardising measurement of 
alcohol-related troubles’ (SMART) project was 
launched in 2008 and receives funding from 
the EU public health programme (2).
The EMCDDA participated as observer in the 
SMART conference on alcohol survey 
Studies show that between a third 
and one half of daily cannabis 
users fulfil dependence criteria
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(1) Czech Republic, Germany, Ireland, Spain, France, Italy, Hungary, the Netherlands.
(2) Germany, France, the Netherlands, Poland — see Drugnet Europe No 63 and 67.
methodology organised on 19 October in 
Barcelona, where the results of a pilot survey 
on alcohol use and related problems in nine 
countries were presented (3). Among others, 
this survey tested the cultural relevance and 
feasibility of three consumption measures:
U  beverage specific quantity frequency; 
U  graduated frequency; and
U  last-occasion approach. 
A model questionnaire was adopted at the 
meeting, designed for use in specific drinking 
surveys or as a component of other health 
surveys carried out at national, regional and 
EU levels. 
The feasibility of this questionnaire will now 
be discussed at various fora, including a 
meeting of the European Commission’s 
Committee on National Alcohol Policy and 
Action.
Janusz Sierosławski and Jacek Moskalewicz
Pioneering work in this area began in 2002 in 
some countries (2) where psychometric scales — 
short instruments to assess heavier patterns of 
drug use — were incorporated into population 
surveys and tested. Results of this work were 
reported regularly to the EMCDDA expert group 
on ‘Prevalence and patterns of drug use among 
the general population’. In recent years, the 
EMCDDA has actively promoted and supported 
the translation, adaptation and validation of 
such scales in additional countries, in pursuit of 
a common European approach.
Danica Klempová
(1) Although the EMCDDA focuses mainly on illicit 
substances, some of its key indicators (e.g. population 
surveys) also collect information on alcohol.
(2) www.alcsmart.ipin.edu.pl. SMART receives a grant from 
the European Executive Agency for Health and Consumers 
(agreement 2007308). The leading partner in the project is 
the Institute of Psychiatry and Neurology, Warsaw.
(3) Czech Republic, Germany, Estonia, Ireland, Spain, Italy, 
Hungary, Poland, Finland, UK. 
3Responses
Policies and clinical practices in the treatment of 
cannabis-related problems
A new European Society for Prevention Research
Health in prisons
Around 23 million Europeans have used 
cannabis in the last year and some 4 million are 
estimated to be daily or almost daily users. 
Furthermore, around one fifth (21 %) of clients 
entering specialised drug treatment report 
cannabis as their main problem drug (around 
85 000 clients). Yet, despite the large number of 
users potentially in need of assistance for 
cannabis use, and recent developments in this 
area of treatment, providing adequate support to 
this client group remains a challenge.
One of the key roles of the EMCDDA is to 
stimulate the sharing of best practice across the 
Member States. In partnership with the Hungarian 
national focal point, the EMCDDA hosted a 
meeting in Lisbon on 26 January, focusing on 
policies and clinical practices in the treatment of 
cannabis-related problems (1). Practitioners and 
researchers from the Czech Republic, Denmark, 
Germany, Spain, France, Hungary and the 
Netherlands exchanged national experiences in 
this area and discussed the latest developments in 
cannabis treatment approaches.
Bringing cannabis users into contact with the 
treatment system as a matter of priority in national 
policy was underlined as an important step.  
Also raised was the need to evaluate available 
interventions and develop specific guidelines.  
A central topic during the meeting was how to 
balance the use of generic treatment services 
with cannabis-specific programmes. Finally, 
attracting hard-to-reach cannabis users into 
treatment was highlighted. Experiences with 
Internet-based and other targeted interventions 
were shared in this context.
Alessandro Pirona, Teodora Groshkova 
and Anna Peterfi
A new European Society for Prevention 
Research (EUSPR) was formally established by 
the Polish authorities on 30 December within 
the Institute of Psychiatry and Neurology in 
Warsaw. This international non-profit 
organisation is devoted to quality in 
prevention education and research and to 
promoting the active dissemination of 
research results to communities. 
The EUSPR’s mission, membership, future 
activities and alliances, were discussed at its 
first conference and members’ meeting in 
Amsterdam from 10–11 November, attended 
by the EMCDDA (1).
European prevention researchers participating 
in the meeting considered that the EUSPR 
should support the implementation of 
evidence-based practice and back evidence-
based recommendations. It could also assist 
the EMCDDA in selecting the most effective 
The German drug commissioner,  
Mechthild Dyckmans, was among 
120 experts attending a workshop on  
‘drugs and imprisonment’, organised by the 
German national focal point with the support 
of the Ministry for Health on 19 November in 
Berlin (1). The EMCDDA was represented at 
the event, along with prison health and social 
services, NGOs and policy bodies.
Presentations revealed that gaps remain in 
drug service provision inside prisons, a fact 
aggravated by budget restraints and 
shortages in staff. Yet opiate substitution 
treatment (OST) appears increasingly 
accepted inside prisons. An example from the 
Federal State of North Rhine-Westphalia 
showed that strategic approaches can make 
a difference. In this Land, the proportion of 
prison inmates in substitution treatment 
increased from 5 % to 17 % in only three 
years. 
The acute risk of death among newly 
released prisoners through overdose was also 
examined. Raising awareness of these risks 
and providing a seamless transition to 
external drug treatment, can play a key role 
in reducing drug-related deaths in this high-
risk group.
Roland Simon
prevention programmes and promoting them 
in Europe. There is now much evidence that 
interventions can be transferred to other 
countries or continents. However, clear and 
useable guidelines are much needed for the 
successful implementation of exogenous 
prevention programmes.
The EUSPR has the potential to better connect 
European prevention researchers to national 
and European policymakers and to each 
other. This could facilitate the EMCDDA’s 
information collection and dissemination in 
future. 
The next EUSPR conference will be held at the 
EMCDDA from 8–9 December 2011.
Gregor Burkhart
(1) www.emcdda.europa.eu/html.cfm/index121810EN.html
Internet-based interventions,  
a new way of attracting cannabis 
users into treatment
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(1) www.euspr.org (1) www.dbdd.de/content/view/102/123/
Gaps remain in drug service 
provision inside prisons
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Leading European experts in the drugs field 
come together in this edition of the quarterly 
review Sécurité globale (Global security) to 
analyse the issue of anti-drug strategies. 
Through a collection of essays, the work 
describes how European coordination is a 
must in addressing today’s drugs problem.
Georges Estievenart, founder and honorary 
Director of the EMCDDA, charts the EU’s 
progression from an awakening to the drugs 
issue to the implementation of sophisticated 
strategies and action plans. In his article, he 
describes the EU strategy in the global 
context. Other contributors include: ex-Europol 
Deputy Director, Willy Bruggeman, who 
explores the fight against drug trafficking as 
the core of Europol’s work; and former 
EMCDDA analyst and current Scientific 
Committee member, Henri Bergeron, who 
describes the Europeanisation and 
convergence of drug policies.
Further issues explored in the review include: 
‘The French contribution to the EU’s role in the 
fight against drugs’; ‘Cocaine production and 
trafficking — what do the statistics tell us?’ 
and ‘European penal law and the fight 
against drug trafficking — myth or reality?’ 
Publisher: Choiseul éditions 
Language: French
Price: EUR 28 
Date: No 13, autumn 2010
ISBN: 978-2-36259-006-1
Ordering information:  
www.choiseul-editions.com
The EMCDDA is responsible for the selection 
of materials for the Bookshelf and for the text 
presented. However, responsibility for the content 
of these materials and the opinions expressed 
therein lies with the authors themselves.
Bookshelf
Sécurité globale: 
Stratégies anti-drogues
Feature
2011 work programme — in step with today’s drugs 
problem
The EMCDDA’s 2011 work programme 
takes forward activities launched in 2010 
to implement the agency’s three-year 
strategy and work plan for 2010–12.  
This strategy seeks to: consolidate and 
deepen the analysis of core data sets 
held at the EMCDDA; invest in more 
complex and policy-relevant analysis; 
and develop a small number of new 
areas of strategic importance. It also 
reflects on the obligations of the agency’s 
mission statement and is sensitive to the 
needs of the EU drugs strategy and 
action plan (2009–12).
The purpose of the 2011 work 
programme, adopted by the EMCDDA 
Management Board in December 2010, 
is to map activities to be undertaken this 
year and establish the methods needed 
to attain the goals set for 2012. It is 
structured around the substantive work 
areas set out in the three-year strategy, 
including: monitoring the drug situation 
and responses; monitoring and 
evaluating drug policies, laws and 
interventions; tracking new drugs and 
trends; and developing guidelines and 
best practice.
Priority is given in the 2011 work 
programme to the efficient collection and 
analysis of key indicator data and to 
maintaining the technical networks that 
sustain them. Of equal importance are 
the core instruments that allow the 
EMCDDA to report on Member States’ 
responses to the drugs problem.
‘A central consideration for the EMCDDA 
is to ensure that the reporting system 
remains relevant to European needs’, says 
EMCDDA Director Wolfgang Götz, 
announcing that ‘a top-level strategic 
review of the current reporting system will 
begin this year’. Here, the Reitox network 
will act as the main interface between 
the EMCDDA and national data 
collection and expertise. 
The monitoring of supply reduction 
activities will also be taken forward in 
2011, following important groundwork in 
2010 (see page 2). 
Other themes to be developed throughout 
the year will include polydrug use (moving 
beyond the traditional substance-specific 
perspective) and different types of addiction. 
An EMCDDA Insights publication on 
understanding drug use in the context of 
models of dependency and compulsive 
behaviour is planned for 2011. 
Finally, the European Commission will launch 
an external evaluation of the EMCDDA in 
the course of the year. The EMCDDA will 
provide support to the Commission and the 
external evaluator in this exercise.
Monika Blum
EMCDDA Director Wolfgang Götz: 
‘Our reporting system must remain
relevant to European needs’
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Work programme 2011, available in English at
www.emcdda.europa.eu/html.cfm/index121903EN.html
Budget 2011, available in English at
www.emcdda.europa.eu/html.cfm/index122190EN.html
The EMCDDA Management Board adopted a total
budget of EUR 16.3 million for 2011.
5Drugs-Lex
Poland passes new law to control ‘head shops’ and ‘legal highs’
A new law entered into force in Poland on 
27 November, eliminating the open sale of 
psychoactive substances not controlled under 
drug laws (‘legal highs’) (1). The new law came 
in the wake of 3 500 inspections by the Polish 
police and state sanitary inspectors in October 
2010, resulting in the closure of 1 200 ‘head 
shops’ (2). The inspections had been prompted 
by reports from Polish hospitals in the second 
half of 2010 of poisonings apparently caused 
by these substances.
As is the case with a law passed on ‘head 
shops’ in Ireland in August 2010, the new 
Polish legislation penalises suppliers rather 
than users. While the law in Ireland adopts a 
criminal-law-enforcement stance, the new law 
in Poland takes a health-protection approach. 
It modifies two existing legislative acts.
Article 1 of the new law modifies the ‘Act on 
Counteracting Drug Addiction’. Essentially the 
revised legislation prohibits the manufacture, 
advertising and introduction of ‘substitute drugs’ 
into circulation (3). The penalty for 
manufacturing such drugs or introducing them 
into circulation is a fine by the state sanitary 
inspector of between 20 000 and one million 
Polish złoty (± EUR 5 000 to 250 000).  
The penalty for advertising them is up to one 
year in prison. (The law makes no specific 
reference to whether the drug should first be 
considered as harmful).
Article 2 of the new law modifies the ‘Act on 
State Sanitary Inspection’. Previously the state 
sanitary inspectors were empowered to act 
against any ‘failure to meet hygiene and health 
requirements’. As a result of the modification, 
they now have the specific right to withdraw from 
trade a ‘substitute drug’ for up to 18 months in 
order to assess its safety, if there is a justified 
suspicion that it might pose a threat to life or 
health. The costs of the assessment are met by the 
distributor in the event that the drug is harmful.  
If the drug is found to be harmless, the cost will be 
reimbursed by the state. The inspectors also have 
the right to close premises for up to three months.
Brendan Hughes and Artur Malczewski
Partners International
Russian drugs agency visits 
EMCDDA
Training on building national drug 
observatories in the Southern Mediterranean
Drug trafficking routes, chemical precursors and building 
national and regional drug information systems were 
among the topics discussed during the latest visit to the 
EMCDDA of its Russian partners on 21 January.  
The visiting delegation, from the Federal Drug Control 
Service (FDCS) of the Russian Federation, was headed by 
FDCS Vice-Director Oleg Safonov.
The EMCDDA and the FDCS cooperate under a 
Memorandum of Understanding signed in October 2007 (1). 
Under this agreement, the two bodies collaborate in a 
number of areas, including: new drug types and emerging 
drug use trends; and the prevention of drug-related crime. 
The meeting allowed participants to discuss developments in 
collaboration under the MoU as well as to explore technical 
issues. Fruitful exchanges were held on the topics of supply 
and supply reduction, the health and social responses to 
drug use and new drugs. On the latter, the FDCS showed 
particular interest in being linked to the European early-
warning system on new drugs. Russian experts will be invited 
to participate in the EMCDDA’s 1st International 
multidisciplinary forum on new drugs to be held from  
11–12 May in Lisbon.
Cécile Martel
(1) See news release No 6/2007.
Training on building national drug observatories in Southern Mediterranean countries was 
delivered at a technical meeting in Rabat in December 2010. The event came one month 
after the launch of an EMCDDA handbook on Building a national drugs observatory and 
the agency’s first seminar on technical cooperation with the European Neighbourhood 
Policy (ENP) countries (see page 6). The Rabat meeting took place in the context of a 
MEDNET seminar, organised by the Pompidou Group of the Council of Europe (1).  
The seminar, the first to be organised in Morocco by the Pompidou Group, gathered 
participants from Algeria, Cyprus, Egypt, France, Italy, Jordan, Lebanon, Malta, Morocco 
and Portugal. 
Representatives of the EMCDDA and the national focal points (NFPs) of Cyprus, France and 
Italy shared their experience of building national drug observatories in the EU perspective, 
with a specific focus on strategic challenges and operational core functions. With the 
support of the EMCDDA and the NFPs, these experiences were discussed by each national 
delegation in workshops, before being debated in plenary.
While the members of the MEDNET network will continue their activities under the umbrella 
of the Pompidou Group, it is expected that countries interested by the EU offer to establish a 
closer relationship with the EMCDDA (2) will be formally consulted as a preliminary step to 
begin technical cooperation. Algeria and Morocco have already expressed their wish to 
develop bilateral cooperation with the EMCDDA. Other Southern ENP countries could 
follow suit in 2011. 
Alexis Goosdeel
(1) For a description of the MEDNET network see www.coe.int/t/dg3/pompidou/activities/mednet_en.asp
(2) In March 2007, the Council of the EU agreed on the gradual participation of ENP partner countries in the work of 
EU agencies to encourage administrative reform and promote convergence of ENP partners’ policies with EU norms.
(1) Act of 8 November 2010, (Dz.U. z 2010 nr 213 poz. 1396)
www.narkomania.gov.pl/portal?id=15&res_id=1005097
(2) Retail outlets specialised in ‘legal highs’ and drug 
paraphernalia.
(3) The term ‘substitute drug’ is redefined in the new law as a 
substance or plant used instead of, or for the same purposes 
as, a controlled drug, and whose manufacture or placing on 
the market is not regulated by separate provisions.
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Creating a network of regional drug 
observatories in Italy was the focus of the 
latest Reitox Academy held in Lisbon from 
13–15 December. Representatives from all 
Italian regions participated in the academy 
which was organised by the EMCDDA 
and the Italian anti-drug policies 
department of the Presidency of the 
Council of Ministers. The event took place 
in the context of a broader project to 
create a national network of drug 
monitoring centres in Italy.
Professor Giovanni Serpelloni, Head of the 
anti-drug policies department, declared: 
‘The idea of an Italian network of regional 
drug observatories stems from the need to 
establish a national monitoring system that 
organises drug-related data collection, 
analysis and reporting in a participative 
and coordinated way, taking into account 
the structure of the state and the diversity of 
the regions’. 
All participants received Building a national 
drugs observatory, the EMCDDA’s practical 
guide to setting up such structures (see  
page 7). This had been translated into Italian 
by the national focal point for the event  
and enabled participants to look at the 
procedures for creating national and regional 
observatories and to discuss their functions. 
This Reitox academy was the first to be 
organised at the request of a Member State 
to promote and disseminate the handbook. 
The Academy will feed reflection on the 
future development and consolidation of the 
Reitox network as set out in a development 
strategy for the network for 2010–15  
(see Drugnet Europe No 69).
Alexis Goosdeel and  
Elisabetta Simeoni
Spotlight
Towards an Italian 
network of drug 
observatories
Reitox
Best practice
Cooperation with Europe’s closest neighbours
What it is, what it isn’t
Perspectives for technical cooperation 
between the EMCDDA and the 16 European 
Neighbourhood Policy (ENP) partner 
countries were explored in 2010, with a 
particular focus on institution-building and 
boosting drug monitoring capacity. The 
EMCDDA has now embarked on a follow-up 
phase, drawing on the results of a seminar 
held in the context of the ENP in October (1). 
Organised by the EMCDDA, in cooperation 
with the European Commission, the seminar 
was financed by the Commission’s Technical 
Assistance and Information Exchange 
Instrument (TAIEX) (2). In the wake of the event, 
the EMCDDA will consult all ENP countries to 
gauge the potential for establishing bilateral 
cooperation frameworks. Cooperation 
between the EMCDDA and an interested 
ENP partner country will only proceed if 
certain conditions are observed. For example, 
objectives and desired results of the 
cooperation need to be clearly defined and 
the EMCDDA must demonstrate the added 
value it can bring to the partner country’s 
policy commitments, actions and investments. 
The state of development of national drug 
information systems (NDIS) and national drug 
observatories (NDO) among the ENP 
countries differs greatly. Some countries 
conduct little or no monitoring and the 
concept of an NDO is not yet defined. 
Preliminary information and datasets are 
available in others but in the absence of an 
NDO. In a third group, countries report data-
collection and reporting capacity as well as 
an established NDO, although these may 
require consolidation.
The EMCDDA is one of 16 EU agencies 
which are ‘open’ to the participation of ENP 
partner countries. To facilitate cooperation 
between these agencies and ENP partner 
countries, the European Commission has 
allocated EUR 3.7 million to a specific 
programme under inter-regional cooperation 
(East and South) for the period 2011–13.
Cécile Martel
‘Best practice is the best application of available evidence to current activities in the drugs field’. 
This is according to a group of experts tasked with developing a working definition of the 
concept when responding to drug use. The group, meeting in Lisbon on 17 November, included: 
the Chairman of the EMCDDA Management Board João Goulão; members of the EMCDDA 
Scientific Committee; policymakers; and top-level researchers in the areas of treatment, 
prevention and harm reduction. According to the definition agreed, five points should be 
considered before applying the term best practice to an intervention, namely:
U  underlying evidence should be relevant to the problems and issues affecting those involved 
(professionals, policymakers, drug users, their families);
U  methods should be transparent, reliable and transferable and all appropriate evidence 
should be considered in the classification process;
U  experience in implementation, adaptation and training should be systematically collected 
and made available;
U  contextual factors should be studied by modelling different prevalence levels so as to assess 
the impact of an intervention on the population; and
U  evidence of effectiveness and feasibility of implementation should both be considered for the 
broader decision-making process.
Highlighted in the discussions were the many factors to be taken into account when identifying 
and promoting best practice, such as how to export experiences to different contexts.
Marica Ferri
(1) ‘The EU drug monitoring system, the EMCDDA and 
perspectives for cooperation with ENP countries’.
(2) http://ec.europa.eu/enlargement/taiex/index_en.htm
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Useful materials  
or events on the 
drugs issue
IHRA international 
conference
‘Building capacity, redressing 
neglect’ will be the theme of 
the 22nd international 
conference of the International 
Harm Reduction Association 
(IHRA) to be held in Beirut from 3–7 April. While 
harm reduction has been adopted in policy and 
practice in more countries than ever before, 
significant gaps remain. This year’s conference 
will contain a strong focus on capacity-building 
among civil society to implement harm reduction 
and on women and marginalised populations.
For more, see www.ihra.net/conference
ISSDP conference 2011
The 5th annual conference of the International 
Society for the Study of Drug Policy (ISSDP)  
will take place in Utrecht from 23–24 May. 
Organised by the Trimbos Institute, the event 
will focus on supply reduction indicators; harm 
reduction principles and practices in the supply 
field; and improving and utilising cross-national 
comparisons of problems and policies.
For more, see www.trimbos.org/trimbos-international/
agenda/issdp-conference-2011
European HIV Conference
‘HIV in the European region: unity and diversity’, 
is the focus of the major European conference to 
take place in Tallinn from 25–27 May. The event 
is organised by the Estonian National Institute for 
Health Development in cooperation with the 
World Health Organization, the United Nations 
Office on Drugs and Crime (UNODC), the Joint 
United Nations Programme on HIV/AIDS 
(UNAIDS) and other international organisations. 
The EMCDDA sits on the Scientific Board and 
Organising Committee.
For more, see www.aids2011.com/en/home 
www.facebook.com/aids2011
Organisations wishing to publicise their 
newsletters, magazines, websites, CD-ROMs 
or any other resources are invited to contact 
Kathryn.Robertson@emcdda.europa.eu
Products and services
EU agencies — the way ahead
European agencies have been set up in 
successive waves since the mid-1970s and 
today form an important part of the EU’s 
institutional landscape. Responding to 
needs identified by the EU and its Member 
States, they perform a variety of legal, 
technical and scientific tasks across a 
broad range of policy areas. At an 
exhibition at the European Parliament 
(31 January–3 February), the agencies 
presented in thematic clusters how they work together on a broad range of policy issues and 
impact on the lives of Europe’s 500 million citizens. The event was coordinated by the 
EMCDDA, in its capacity as chair of the agencies’ Heads of Communication and Information 
Network (HCIN). On 1 March, the European Chemicals Agency will take over the one-year 
presidency of the HCIN. 
For more on the event, see www.emcdda.europa.eu/eu-agencies-the-way-ahead
Building a national drugs observatory
The EMCDDA and the Inter-American Drug Abuse Control Commission 
(CICAD) of the Organisation of American States (OAS) launched in 
Montevideo on 18 October Building a national drugs observatory: 
a joint handbook. Based on the experience of the two bodies in 
establishing drug observatories in their respective geographical areas, 
the handbook provides a practical guide to setting up such structures. 
Relevant for all world regions, the handbook is complemented by an 
online toolbox to ensure the continued exchange of experience and 
best practice.
Available in Spanish, English, French, Italian, Croatian and Turkish. Coming soon in Arabic and Russian. 
www.emcdda.europa.eu/news/2010/8 — www.emcdda.europa.eu/publications/joint/ndo-handbook
First European conference on drug 
supply indicators — key conclusions
The First European conference on drug supply indicators (20–22 
October) laid the foundations for establishing a set of technically sound 
and sustainable indicators for monitoring drug markets, crime and 
supply reduction in Europe (see page 2). The key conclusions of the 
event, organised by the European Commission and the EMCDDA,  
are now available. 
Available in English at www.emcdda.europa.eu/publications/supply-indicator-conference-2010/conclusions
Mephedrone risk-assessment report
In 2010, mephedrone become the first cathinone derivative to be ‘risk-assessed’ by the 
extended Scientific Committee of the EMCDDA as part of a three-step process established by 
Council Decision 2005/387/JHA. On 2 December (see page 1) it was banned across 
Europe (the second substance after BZP to have been controlled under this mechanism).  
The Report on the risk assessment of mephedrone in the framework of the Council decision on 
new psychoactive substances is now available.
Available in English at www.emcdda.europa.eu/publications/risk-assessments
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EMCDDA meetings
26 January:  European exchange on policies and practices 
in the treatment of cannabis-related problems, 
Lisbon.
28 January:  2nd European meeting on wastewater 
analysis, Lisbon.
1–2 February:  EMCDDA expert meeting on the revision of 
the treatment demand indicator, Lisbon.
1–2 March:  Reitox Academy on ‘Drug use among the 
prison population: scope and responses’, 
Lisbon.
16–17 May: EMCDDA Scientific Committee, Lisbon.
External meetings
21–25 March:  54th session of the UN Commission on 
Narcotic Drugs, Vienna.
23–25 March:  13th International symposium on substance 
abuse treatment, Barcelona.
3–7 April:  Harm reduction 2011: 22nd international 
conference, International Harm Reduction 
Association, Beirut (www.ihra.net/conference).
23–24 May:  5th annual conference, International Society 
for the Study of Drug Policy (ISSDP), Utrecht  
(www.trimbos.org/trimbos-international/
agenda/issdp-conference-2011).
25–27 May:  ‘HIV in the European region: unity and 
diversity’, Estonian National Institute for Health 
Development, Tallinn 
(www.aids2011.com/en/home).
EU meetings
1 March:  Horizontal working group on drugs, Brussels.
5 April:  Horizontal working group on drugs, Brussels.
6 April:  Political dialogue with Central Asian countries, 
Brussels.
3 May:  Horizontal working group on drugs, Brussels.
Scientific Committee: ‘EMCDDA work 
programme grows in strength and quality’
‘The EMCDDA work programme continues to grow in strength and 
quality and covers an appropriate range of policy-relevant topics’.  
So stated the EMCDDA Scientific Committee at its latest meeting in 
Lisbon from 15–16 November. The declaration came in a formal opinion 
on the 2011 programme, which acknowledges the programme’s focus 
on scientific outputs.
Challenges in assessing the risks of new drugs were also among the 
issues reviewed at the meeting. Here, discussions centered on the results 
of a questionnaire to the Committee on the scientific aspects of the risk-
assessment procedure under the Council Decision on the information 
exchange, risk-assessment and control of new psychoactive substances. 
A Scientific Committee opinion on the issue was drawn up in the context 
of an ongoing assessment of the Council Decision to be concluded later 
this year by the European Commission.
Upcoming EMCDDA publications in the area of treatment were also 
presented. To be published in the agency’s Insights series, these will 
cover various aspects of treatment, including: heroin-assisted treatment; 
therapeutic communities and residential care; and social rehabilitation. 
Margareta Nilson
(1) Meeting documents are available at www.emcdda.europa.eu/html.cfm/index51814EN.html
Discussions at the meeting focused on how European research and 
networking in this area could be facilitated. Potential new uses of the 
technique were also explored, such as to inform analysis on the size of the 
drug market or to identify the use of new psychoactive substances in 
communities.
Ana Gallegos and Jane Mounteney
www.emcdda.europa.eu/publications/insights/wastewater
Continued from page 1
Wastewater analysis, an emerging science
(1) For example, in mass spectrometry and high-performance liquid chromatography.
New prize for top scientific papers 
Europe’s top scientific papers on drug-related topics will be 
acknowledged this year in a new initiative launched by the EMCDDA 
and its Scientific Committee. The annual prize giving, to take place in 
Lisbon in November, will celebrate excellence in scientific writing on 
drugs. The articles will have been published in 2010 in peer-reviewed 
scientific journals, with the primary author based in an EU Member 
State or Norway. For full details, see the EMCDDA homepage. 
